The Small Molecule CMO/CDMO Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Small Molecule CMO/CDMO Market:
https://www.thebusinessresearchcompany.com/report/small-molecule-cmo-or-cdmo-global-market-report
According to The Business Research Company’s Small Molecule CMO/CDMO Global Market Report 2024, The small molecule cmo/cdmo market size has grown strongly in recent years. It will grow from $46.83 billion in 2023 to $50.58 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to favorable government support, cost-effective solutions, growing complexity in drug development, industry consolidation, focus on core competencies.
The small molecule cmo/cdmo market size is expected to see strong growth in the next few years. It will grow to $68.04 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rise in drug pipelines, globalization of pharmaceutical operations, demand for flexible manufacturing, regulatory compliance expertise, biopharmaceutical convergence. Major trends in the forecast period include sustainable and green manufacturing practices, increased collaboration and partnerships, personalized medicine and niche therapies, rise in virtual and virtual-to-reality companies, integration of digital technologies, rapid response manufacturing.
The rising demand for pharmaceuticals is expected to propel the growth of the small-molecule CMO/CDMO market going forward. The pharmaceutical industry is a sector that involves the discovery, development, and production of drugs and medicines by both governmental and private entities. Small-molecule CMO/CDMO is used in the pharmaceutical industry to outsource various services, including the development, manufacturing, and packaging of small-molecule drugs, allowing pharmaceutical companies to reduce costs, save time, and streamline processes. For instance, in May 2021, according to reports published by IQVIA Inc., a US-based pharmaceutical company, the projected total expenditure on pharmaceuticals in the US is anticipated to range between $380 to $400 billion by the year 2025, up from $359 billion in 2020, reflecting a compound annual growth rate of 3%. Therefore, the rising demand for pharmaceuticals is driving the growth of the small-molecule CMO/CDMO market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13733&type=smp
The small molecule cmo/cdmo market covered in this report is segmented –
1) By Product: Small Molecule Drug Product, Small Molecule API
2) By Stage Type: Clinical, Commercial, Preclinical
3) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Cardiovascular Disease, Respiratory Disorders, Metabolic Disorders, Other Therapeutics
4) By Application: Cardiovascular, Oncology, Diabetes, Immunological Disorders
Top Major Players
Patheon NV (Thermo Fisher Scientific)
GlaxoSmithKline
Johnson Matthey PLC
Lonza Group Ltd.
WuXi AppTec
Major companies operating in the small-molecule CMO/CDMO market are focusing on innovative technologies, such as the state-of-the-art small-molecule platform in Shanghai, to elevate CDMO services. The state-of-the-art small-molecule platform represents the forefront of technological innovations to develop and produce small-molecule drugs and to create safer, more effective, and more efficiently produced pharmaceutical compounds. For instance, in June 2023, Porton Pharma Solutions Ltd., a China-based pharmaceutical company, launched a state-of-the-art small-molecule platform in Shanghai, elevating CDMO services. A state-of-the-art small molecule platform embodies a holistic approach, combining cutting-edge technologies and methodologies to advance the entire lifecycle of small molecule pharmaceuticals and one-stop-shop solutions, an end-to-end platform, flexibility and availability, and digital transformation.
The small molecule cmo/cdmo market report table of contents includes:
1. Executive Summary
2. Small Molecule CMO/CDMO Market Characteristics
3. Small Molecule CMO/CDMO Market Trends And Strategies
4. Small Molecule CMO/CDMO Market - Macro Economic Scenario
5. Global Small Molecule CMO/CDMO Market Size and Growth
...........................
32. Global Small Molecule CMO/CDMO Market Competitive Benchmarking
33. Global Small Molecule CMO/CDMO Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Small Molecule CMO/CDMO Market
35. Small Molecule CMO/CDMO Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
We have some expertise in taking care of medication substances, tranquilize items, and almost all dose structures including tablets, containers, semi-solids, parenterals, clean, transdermal, and inward breath items.
Our gadget masters administer routine synthetic and practical testing of bundling (elastomers, glass, plastics) and segment testing.
We additionally help with merchant and agreement maker capability.
These basic administrations are the reason Avecia Pharma has earned a strong notoriety in the business since 1988.
